PolyNovo (ASX:PNV) is a medical device company that develops and manufactures regenerative medical products for the treatment of burns, chronic wounds, and soft tissue defects. The company's flagship product is the NovoSorb® dermal substitute, which is a biodegradable matrix that helps to promote wound healing. PolyNovo's operations focus on the development and commercialization of its regenerative medical products. The company has a strong pipeline of products in development, including treatments for diabetic foot ulcers, pressure sores, and venous leg ulcers. PolyNovo also has a number of clinical trials underway to evaluate the safety and efficacy of its products.